Alto Neuroscience Inc (ANRO)

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary...

Form 8-K - Current report

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated – – New ALTO-101 analyses support significant effects on...

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD...

Form EFFECT - Notice of Effectiveness